Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12445299 | 0.88 | CRHBP (0.39) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL20434855 | 0.81 | CRHBP (0.35) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL29317640 | 0.81 | CRHBP (0.35) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL680047 | 0.77 | CRHBP (0.39) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL18878034 | 0.76 | CRHBP (0.40) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL12127018 | 0.74 | CRHBP (0.38) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL24928385 | 0.72 | CRHBP (0.37) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL20434854 | 0.72 | CRHBP (0.41) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL12445308 | 0.72 | GRIN2D (0.35) | — | |
| SCHEMBL20434850 | 0.70 | CRHBP (0.35) | CRHBPCRHR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | Frequency Therapeutics, Inc. | 2021-09-30 | — | — | US | disclosed |
| US-11066419-B2 | 1H-pyrrole-2,5-dione compounds and methods of using same | Frequency Therapeutics, Inc. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200316089-A1 | 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20190352313-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | Frequency Therapeutics, Inc. | 2019-11-21 | — | — | US | disclosed |
| US-20180214458-A1 | 1,5-DIHYDRO-2H-PYRROL-2-ONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | MCL1, PROX1, MKI67 | CRHBP 1311/4885CRHR2 2144/4885ALDH1A1 65/4885 |
| US-20180214458-A1 | 1,5-DIHYDRO-2H-PYRROL-2-ONE COMPOUNDS AND METHODS OF USING SAME | DCX, MKI67, MCL1 | CRHBP 2203/4885CRHR2 3218/4885ALDH1A1 33/4885 |
| US-20200316089-A1 | 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME | DCX, MCL1, MKI67 | CRHBP 3681/4885CRHR2 4418/4885ALDH1A1 61/4885 |
| US-11066419-B2 | 1H-pyrrole-2,5-dione compounds and methods of using same | MKI67, PROX1, DCX | CRHBP 2091/4885CRHR2 2048/4885ALDH1A1 30/4885 |
| US-20190352313-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | MCL1, PROX1, MKI67 | CRHBP 1311/4885CRHR2 2144/4885ALDH1A1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.